We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Premature Birth Predicted by Immunoassay

By LabMedica International staff writers
Posted on 03 Oct 2012
Print article
A blood test has been developed that can predict the likelihood that women with intact membranes with threatened preterm labor will deliver spontaneously within seven days of sampling.

The test is based on testing maternal serum for specific proteins, using multiplex sandwich immunoassay based on flowmetric multiplex technology, which has been used to analyze multiple inflammatory markers and neurotrophins in maternal serum in women with threatened preterm labor (PTL).

From 1996 to 2005, an international team working at the Sahlgrenska University Hospital (Gothenburg, Sweden) enrolled 142 healthy women without major medical problems. The women were with singleton pregnancies presenting with threatened PTL between 22 weeks plus 0-7 days and 33 weeks plus 6-7 days of gestation. The assays were based on a newly developed blood test that looks at specific proteins in the woman's blood combined with an already established examination that uses ultrasound to measure the length of the cervix.

Only proteins with detectable maternal serum levels in more than 50% of the samples were included in the analyses. Therefore, interleukins (IL) such as IL-1b, IL-2, IL-5, IL-6, and IL-8 were excluded from further analyses. The statistically highest significant values were detected for IL-10, matrix metalloproteinasis-9 (MMP-9) and migration inhibitory factor (MIF). In the prediction model, levels of maternal serum IL-10 were significantly higher in women who delivered preterm within seven days of sampling, compared with women who delivered later. The study also showed that found that levels of maternal serum chemokine (C-C motif) ligand 5 (RANTES) were statistically higher in women who delivered compared with women who delivered later.

Panagiotis Tsiartas, MD, PhDc, the senior author of the study said, "To have time to give the woman cortisone, which speeds up the development of the fetal lungs, it is common practice to delay the delivery by a couple of days with the help of tocolytic treatment or anti-contraction medications. Being able to predict if a woman who comes to the hospital with preterm contractions will actually give birth early and thereby requires follow-up and possible treatment is therefore very important. Statistically, the method can predict with 75% to 80% accuracy if a woman will give birth early." The study was published September 2012 issue of the British Journal of Obstetrics and Gynaecology.

Related Links:

Sahlgrenska University Hospital


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
New
PROM Test
AMNIOQUICK DUO
New
Ross River Virus Test
Ross River Virus Real Time PCR Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: A coronal MRI section shows a high-intensity focused ultrasound lesion in the left thalamus of the brain (Photo courtesy of UT Southwestern Medical Center)

Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries

Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.